乳腺癌穿刺活检与手术标本中ER、PR、HER2分析

Analysis of ER,PR and HER2 in Breast Cancer Biopsy and Surgical Specimens

目的探讨在乳腺癌空芯针穿刺活检(core needle biopsy,CNB)标本与手术切除标本中应用免疫组化检测雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的差异。方法回顾性收集2014年5月—2019年8月接受手术治疗的78例乳腺癌患者临床资料,均为女性患者,所有患者均于术前进行CNB检查,采用免疫组化技术检测CNB标本及手术切除标本ER、PR、HER2表达情况,比较并分析两种检查方式获取的标本免疫组化检测的差异及一致性。结果CNB标本与手术标本检测ER、PR、HER2的表达情况未见显著差异(P>0.05);CNB标本检测ER、PR与手术标本检测结果一致性好,HER2检测结果一致性一般。结论乳腺癌患者CNB标本检测ER、PR、HER2结果可满足分子分型及预后判断的需求,临床可根据CNB检查结果综合考虑治疗方案,有利于肿瘤的精准治疗。

Objective To explore the difference between core needle biopsy(CNB)specimens in breast cancer and immunohistochemical detection of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor 2(HER2).Methods The clinical data of 78 patients with breast cancer who received surgical treatment from May 2014 to August 2019 were collected retrospectively.All patients were examined with CNB before operations.The expression of ER,PR and HER2 in CNB samples and resected samples were detected with immunohistochemistry.The difference and consistency of the two methods were compared and analyzed.Results There was no significant difference in the expression of ER,PR and HER2 between CNB and excision samples(P>0.05).The results of ER and PR were consistent,and HER2 was generally consistent.Conclusion The detections of ER,PR and HER2 using CNB samples of breast cancer patients can meet the needs of molecular typing and prognosis judgment.The clinical treatment plan can be comprehensively considered according to CNB results,which is conducive to the precise treatment of tumor.